Tempus AI (NASDAQ:TEM) Cut to Hold at Stifel Nicolaus

Stifel Nicolaus downgraded shares of Tempus AI (NASDAQ:TEM) from a buy rating to a hold rating in a research report sent to investors on Monday, Marketbeat reports. They currently have $65.00 price objective on the stock, up from their prior price objective of $45.00.

Several other research firms have also recently weighed in on TEM. Needham & Company LLC restated a “buy” rating and set a $47.00 price objective on shares of Tempus AI in a research report on Wednesday, August 7th. Piper Sandler began coverage on Tempus AI in a research report on Monday, August 12th. They set a “neutral” rating and a $40.00 price target on the stock. JPMorgan Chase & Co. upped their price objective on Tempus AI from $42.00 to $47.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Bank of America downgraded Tempus AI from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $45.00 to $60.00 in a research report on Wednesday, October 2nd. Finally, Loop Capital increased their price target on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, October 15th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Tempus AI presently has an average rating of “Moderate Buy” and an average target price of $54.22.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $56.63 on Monday. The stock’s 50-day simple moving average is $51.21. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI has a 12 month low of $22.89 and a 12 month high of $79.49.

Institutional Investors Weigh In On Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of TEM. First Horizon Advisors Inc. bought a new position in shares of Tempus AI during the third quarter valued at approximately $30,000. Vestor Capital LLC bought a new position in Tempus AI in the 3rd quarter worth $153,000. Sandia Investment Management LP purchased a new stake in shares of Tempus AI in the 2nd quarter worth about $136,000. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in shares of Tempus AI during the 3rd quarter valued at about $258,000. Finally, Clarus Group Inc. purchased a new position in shares of Tempus AI during the third quarter valued at about $283,000.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.